AbbVie Inc. filed a Form 8-K with the SEC on October 30, 2026, announcing the release of its financial results for the third quarter ended September 30, 2026.

Key Highlights

  • Filing date: October 30, 2026, reporting on the quarter ended September 30, 2026.
  • Press release furnished: A press release announcing Q3 2026 financial results was furnished as Exhibit 99.1 to the filing.
  • Signed by: Scott T. Reents, Executive Vice President and Chief Financial Officer of AbbVie Inc.
  • Common stock listed: AbbVie common stock ($0.01 par value) trades under the symbol ABBV on the New York Stock Exchange.
  • Senior Notes registered: Six series of senior notes are registered on the New York Stock Exchange, with maturities ranging from 2027 to 2031, under symbols ABBV27, ABBV28, ABBV28B, ABBV29, ABBV31, and additional listed securities.

AbbVie's October 30, 2026 Current Report on Third-Quarter Operations

AbbVie Inc., a Delaware-incorporated company headquartered at 1 North Waukegan Road, North Chicago, Illinois, filed a current report disclosing results of operations and financial condition under Item 2.02 of the SEC's reporting rules. According to the filing, on October 30, 2026, AbbVie issued a press release announcing financial results for the third quarter ended September 30, 2026. That press release was furnished as Exhibit 99.1 and incorporated by reference into the report.

The filing was signed by Scott T. Reents, identified in the document as Executive Vice President and Chief Financial Officer, on behalf of AbbVie Inc., on October 30, 2026. The filing notes that the press release was furnished pursuant to Item 2.02, and also lists the cover page formatted in Inline XBRL as Exhibit 101. The common stock is listed on NYSE:ABBV, and several series of senior notes carrying interest rates between 0.750% and 2.625% and maturities between 2027 and 2031 are also registered on the New York Stock Exchange under their respective trading symbols.

The substantive financial data referenced in the filing is contained within the furnished press release, Exhibit 99.1, which is incorporated by reference but not reproduced in the body of the 8-K itself. The filing does not reproduce specific revenue, earnings, or other quantitative financial results within the current report form.

What Was Disclosed

AbbVie Inc. filed an 8-K on October 30, 2026, to announce Q3 2026 financial results via a furnished press release. The filing identifies Scott T. Reents as CFO and lists the company's registered securities on the New York Stock Exchange.